PMID- 19247846
OWN - NLM
STAT- MEDLINE
DCOM- 20091008
LR  - 20090519
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 44
IP  - 6
DP  - 2009
TI  - MCP-1 and MIP3-alpha serum levels in acute liver failure and molecular adsorbent 
      recirculating system (MARS) treatment: a pilot study.
PG  - 745-51
LID - 10.1080/00365520902770086 [doi]
AB  - OBJECTIVE: The CC chemokines monocyte chemoattractant protein-1 (MCP-1) and 
      macrophage inflammatory protein-3 alpha (MIP3-alpha) may be involved in the 
      pathogenesis of acute liver failure (ALF) and acute-on-chronic liver failure 
      (ACLF). In ALF and ACLF, the molecular adsorbent recirculating system (MARS) has 
      been used to support liver function. Enhancement of MCP-1, as seen in other 
      extracorporeal support systems such as haemodialysis, might thus have mitigated 
      the beneficial effects of the MARS system in acute hepatic failure. MATERIAL AND 
      METHODS: Serum concentrations of MCP-1 and MIP3-alpha were measured in 10 
      patients with ALF or ACLF treated with MARS. Thirteen patients suffering from 
      chronic hepatic failure (CHF) and 15 healthy individuals served as controls. 
      RESULTS: Baseline MCP-1 serum concentrations were significantly increased in ALF 
      and ACLF patients as compared to patients with CHF (p=0.0027 and p=0.0046, 
      respectively) and controls (p=0.0006 and p=0.0012, respectively). MIP3-alpha 
      serum concentrations were also significantly enhanced in the ALF and ACLF groups 
      as compared with those in CHF patients (p=0.0002 and p=0.0003, respectively) and 
      controls (p<0.0001 and p<0.0001, respectively). Moreover, MIP3-alpha levels were 
      significantly increased in CHF patients as compared to controls (p=0.0002). MCP-1 
      and MIP3-alpha concentrations did not change significantly during MARS treatment 
      in ALF and ACLF patients. CONCLUSIONS: The CC chemokines MCP-1 and MIP3-alpha are 
      increased in ALF and ACLF patients. MARS had no effect on MCP-1 and MIP3-alpha 
      serum concentrations in patients with ALF and ACLF, and yielded no evidence of 
      any harmful effects of the increase of these potentially hepatocidal chemokines.
FAU - Roth, Georg A
AU  - Roth GA
AD  - Department of Anaesthesiology, General Intensive Care and Pain Medicine, Center 
      for Physiology, Pathophysiology and Immunology, Medical University of Vienna, 
      Vienna, Austria. georg.roth@meduniwien.ac.at
FAU - Faybik, Peter
AU  - Faybik P
FAU - Hetz, Hubert
AU  - Hetz H
FAU - Ankersmit, Hendrik J
AU  - Ankersmit HJ
FAU - Hoetzenecker, Konrad
AU  - Hoetzenecker K
FAU - Bacher, Andreas
AU  - Bacher A
FAU - Thalhammer, Theresia
AU  - Thalhammer T
FAU - Krenn, Claus G
AU  - Krenn CG
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL20 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL20)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Chemokine CCL20/*blood
MH  - Female
MH  - Humans
MH  - Liver Failure, Acute/*blood
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
EDAT- 2009/02/28 09:00
MHDA- 2009/10/09 06:00
CRDT- 2009/02/28 09:00
PHST- 2009/02/28 09:00 [entrez]
PHST- 2009/02/28 09:00 [pubmed]
PHST- 2009/10/09 06:00 [medline]
AID - 909086361 [pii]
AID - 10.1080/00365520902770086 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2009;44(6):745-51. doi: 10.1080/00365520902770086.